PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.\', \'Dow Research Institute of Biotechnology & Biomedical Sciences, Dow University of Health Sciences, Karachi, Pakistan.\', \'Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan.\', \'Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan.\', \'National Control Laboratory for Biologicals, Islamabad, Pakistan.\', \'Dow University of Health Sciences, Karachi, Pakistan.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.2217/imt-2020-0263
?:doi
?:hasPublicationType
?:journal
  • Immunotherapy
is ?:pmid of
?:pmid
?:pmid
  • 33557591
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.986
?:rankingScore_hIndex
  • 33
?:title
  • Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33557591>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33557591>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all